Mateo Kovacic has revealed that despite the desire to win, he accepts a point and is already looking forward following the goalless Premier League draw with Manchester United. Neither side could ...

Eli Lilly is developing what could be the first oral GLP-1 agonist. Late-stage clinical trial data is coming this year. The stock has a steep valuation despite trading sideways since the summer ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug. Hours after Hims & Hers posted a blog ...

Reserve your spot now. Eli Lilly And Co LLY, on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the ...

Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here. Eli Lilly and Co. has begun selling its blockbuster ...

“Semaglutide generics will be priced almost 95% lower than [Eli Lilly'] current price,” said Vishal Manchanda, senior vice-president, institutional research at Systematix Group. With the drop ...

Eli Roth‘s The Horror Section has acquired “Jimmy and Stiggs,” marking the horror company’s first major deal since launching earlier this month, Variety can exclusively report. Directed ...

By Borys Kit Senior Film Writer There will be blood. And probably lots of it. Filmmaker Eli Roth has launched The Horror Section, a new, all-encompassing horror media company that aims not just to ...

US-based pharmaceutical giant Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, following approval from the Central Drugs Standard Control Organisation (CDSCO).

Eli Lilly stock has generated fantastic returns for investors over the past five years. The company possesses many lucrative growth opportunities to ensure it remains an excellent buy in the years ...

Eli Lilly (NYSE:LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass compounding its blockbuster GLP-1/GIP receptor agonist tirzepatide. Tirzepatide is ...

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...